Navigation Links
Microbix Has Best-Ever Quarterly Sales
Date:10/20/2010

Microbix Has Best-Ever Quarterly Sales


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Medical Pharmaceuticals, Sales Reports Click to view news release full screen  

Microbix Has Best-Ever Quarterly Sales

 

Toronto Biotech Company Also Expects a 15% Increase in Sales Volume for 2011  TORONTO, Oct. 20 /PRNewswire-FirstCall/ - Microbix Biosystems Inc. (MBX:TSX), a biotechnology company focused on virology and biological technologies, reported strong worldwide sales of $1.9 million for the fourth quarter of 2010 ending September 30th (unaudited) fueled by a 15% increase in virology product volume and a 20% increase in demand for its pharmaceutical-grade water products.

This growth was driven by increased demand for Microbix' products following an increase in new diagnostic kit launches by its customers and Microbix' entry into the market for laboratory proficiency testing for viruses in clinical samples. In the quarter, Microbix also expanded into the pharmaceutical solutions market for formulating drugs, for which the Company expects significant growth. 

Based on the strong sales growth at the close of this fiscal year, Microbix projects a 15% increase in worldwide sales for 2011 based on current currency rates.

William J. Gastle, Microbix' Chief Executive Officer, said: "Our strong sales for the quarter and our projected 15% sales increase for next year are based on the Company's decision a few years ago to risk financing and building a new innovative production facility which more than tripled our manufacturing capacity. This new facility has allowed Microbix to produce new products, add new customers and increase product shipments by 40% compared to 2008. It will serve us well as we expect significant growth in the next few years."

To better position its sales force for growth, Microbix has focused its customer outreach on four markets: The United States, Europe, Southeast Asia and China. The Company has brought in experienced representation to grow these markets and the effort has already begun to show results.

With the $2 million investment commitment from a large animal genetics company in the fourth quarter, Microbix livestock semen selection technology stepped closer to its market introduction of LumiSort™. The $ 500,000 upfront payment financed all LumiSort™ activities in fiscal 2010. The Company is in the latter stages of financing of the influenza vaccine production facility in Hunan, China, which will utilize the VIRUSMAX™ technology in its manufacturing process. Discussions with potential partners for the Urokinase thrombolytic drug Kinlytic® are continuing and the Company hopes to be able to announce news in the near future.

Microbix Biosystems Inc. specializes in the development of biological technologies and commercializing them through global partners. The Company has intellectual property in large market biotherapeutic drugs, vaccine technologies and animal reproduction technologies. Established in 1988, Microbix is headquartered in Toronto.

Disclaimer

This press release contains forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements including the risks associated with failure to get regulatory approval, and release, of Kinlytic for distribution in Canada, the US and other regions of the world;; risks inherent in moving onto new markets or developing and launching new products or engaging new partners; risks associated with commercializing the technologies including sales may not reach sales targets or be made at all, there is no guarantee that the Company will complete development of any technology and if it does that it will perform to commercially exploitable levels, other technologies may emerge before any technology developed by the Company enters the market, royalty rates may not be achievable, markets may not sustain demand for any product should world economies shift significantly, market utilization rates may not be reached, market value of products may vary, product launch dates and market utilization timetables may not be met; risks associated with failure to develop and commercialize LumiSort; non-adoption of LumiSort; competition in Microbix' core business; general economic conditions; intellectual property risks including challenges to protecting the Company's intellectual property rights, patents may not provide adequate protection of the Company's intellectual property, may not be successfully prosecuted and may be subject to challenge and risks of infringement of third party rights; risks associated with financing the China joint venture, that includes obtaining all funds needed to launch or complete the project; risks affecting timely and cost effective construction and operation of the Microbix-Hunan facility; risks associated with operating in foreign jurisdictions, including operating in China with its evolving legal and economic infrastructure and the involvement of the Chinese government departments at national, state and local levels in business and economic matters; creating risks associated with various levels of political and economic conditions and other risks including but not limited to, currency exchange rates and restrictions on foreign exchange; high rates of inflation; renegotiation or nullification of existing licenses, permits and contracts; changes in taxation policies; risks associated with repatriation of profits and changing political conditions and governmental regulations; development of competing technologies in all of its business lines, and Microbix' ability to attract and retain qualified employees and management. These forward-looking statements represent the Company's judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements.


'/>"/>

SOURCE Microbix Biosystems Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Microbix Uses Core Business Cashflow To Fund Late-Stage Pipeline To Build Shareholder Value In 2009
2. Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline
3. Microbix Announces A New Technology Platform For The SST Project
4. Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half 09
5. Microbix Files First Patent Applications On Novel Technology Platform For Large Semen Sexing Market
6. Microbix Sales Grow 22% For Nine Months
7. Microbix Pipeline Set To Reach Milestones In 2010
8. Microbix And Hunan Biopharmaceutical To Build Asias Largest Influenza Vaccine Facility
9. Microbix Biosystems Provides a Corporate Update
10. Microbix Biosystems Re-files Annual Results With OSC
11. Microbix Signs Marketing Agreement For Kinlytic(R)(Urokinase) In Growing Middle East Region
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... 2017 , ... Lajollacooks4u is proud to announce it has become the premiere team-building cooking event ... companies around the world, such as Illumina, HP and Qualcomm, and is ranked #1 in ... popularity is due to its new team building format, a way for teams to not ...
(Date:3/23/2017)... March 23, 2017  SeraCare Life Sciences, ... in vitro diagnostics manufacturers and clinical laboratories, ... first multiplexed Inherited Cancer reference material ... by next-generation sequencing (NGS). The Seraseq™ Inherited Cancer ... input from industry experts to validate the ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... selected by the Connecticut Technology Council (CTC) as a 2017 Women of Innovation® ... annual Women of Innovation Awards Dinner. , The dinner recognizes women accomplished in ...
(Date:3/23/2017)... York , March 23, 2017 According ... plasma products and derivatives market is fragmented due to the presence of ... such as Proliant, Thermo Fisher , and Sigma-Aldrich, compete with ... these three companies, collectively, held more than 76% of this market ... As ...
Breaking Biology Technology:
(Date:2/28/2017)... , Feb. 28, 2017   Acuant , a ... globally, announces significant enhancements to new and core technologies ... New products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity ... technology provides the fastest and most accurate capture software ...
(Date:2/28/2017)... 27. Februar 2017  EyeLock LLC, ein marktführendes Unternehmen ... erstklassige biometrische Lösung zur Iris-Erkennung auf der ... LTE auf dem Mobile World Congress 2017 ... in Halle 3, Stand 3E10, vorstellen. ... Qualcomm Haven™ – eine Kombination aus Hardware, ...
(Date:2/26/2017)... , Feb. 25, 2017  Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring, ... and Reentry. "Too often, too many ... and county jails are trying to tackle this ... and friends and family members. While significant steps are ...
Breaking Biology News(10 mins):